Want to join the conversation?
$PFE's cost of sales for 2015 rose by 1% from last year. This increase was primarily due to a rise in sales volumes on inclusion of legacy Hospira operations and sales volume growth of Pfizer legacy products as well as non-recurring charges related to manufacturing plant pension obligations and inventory impairment in Venezuela in 2015.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.